COCP · Cocrystal Pharma, Inc.
$1.09
-0.03 (-2.68%)
At close · Aug 17
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“For the six months ended June 30, 2026, the Company recorded a net loss of approximately $5,463 and used approximately $4,856 of cash in operating activities. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.38M
Shares
19.26M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| James Martin | Co-Chief Executive Officer and Chief Financial Officer | $627,201 |
| Sam Lee | Co-Chief Executive Officer and President | $627,201 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Sam Lee | Co-Chief Executive Officer and President | $621,588 |
| James Martin | Co-Chief Executive Officer and Chief Financial Officer | $621,588 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Sam Lee | Co-Chief Executive Officer and President | $665,000 |
| James Martin | Co-Chief Executive Officer and Chief Financial Officer | $665,000 |
| Gary Wilcox | Former Chief Executive Officer | $131,250 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Gary Wilcox | Former Chief Executive Officer | $563,000 |
| James Martin | Co-Interim Chief Executive Officer and Chief Financial Officer | $492,000 |
| Sam Lee | Co-Interim Chief Executive Officer and President | $462,000 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Sam Lee | President | $241,000 |
| James Martin | Chief Financial Officer | $231,000 |
| Gary Wilcox | Chief Executive Officer | $201,000 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Gary Wilcox | Chief Executive Officer | $558,352 |
| James Martin | Chief Financial Officer | $549,866 |
| Sam Lee | President | $411,536 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| James Sapirstein | Chief Executive Officer | Appointed | 2026-06-09 |
| Dr. Anthony Japour | member of the Company's board of directors | Terminated | 2026-03-13 |
| Fred Hassan | director | Appointed | 2023-04-24 |
Key facts
CIK
1412486
CUSIP
19188J409
13F (30d)
29 filings
29 filers
Visit website
Investor relations